Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 16/20 | 0.53 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.48 |
| ▸ | RAF1 | P04049 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4205781 | 0.84 | BRAF (0.55) | BRAFPDGFRBKDREPHB4 | |
| SCHEMBL3983756 | 0.83 | BRAF (0.58) | BRAFTRPV4RAF1MAPK14 | |
| SCHEMBL3975710 | 0.82 | BRAF (0.57) | BRAFRAF1MAPK14PDGFRBKDR | |
| SCHEMBL3975611 | 0.79 | BRAF (0.51) | BRAFRAF1MAPK14PDGFRBKDR | |
| SCHEMBL3975361 | 0.78 | BRAF (0.52) | BRAFTRPV4RAF1 | |
| SCHEMBL3977839 | 0.77 | ABCG2 (0.54) | BRAFPDGFRBKDRABL1 | |
| SCHEMBL3974567 | 0.77 | BRAF (0.53) | BRAFTRPV4MAPK14PDGFRBKDR | |
| SCHEMBL3977917 | 0.73 | JAK3 (0.64) | BRAFMAPK14PDGFRBKDR | |
| SCHEMBL4194960 | 0.72 | BRAF (0.70) | BRAFPDGFRBKDR | |
| SCHEMBL4190532 | 0.72 | BRAF (0.79) | BRAFPDGFRBKDRABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118276-A1 | THIENOPYRIMIDINES, THIENOPYRIDINES, AND PYRROLOPYRIMIDINES AS B-RAF INHIBITORS | WYETH (US) | 2009-05-07 | — | — | US | disclosed |
| WO-2009059272-A1 | THIENOPYRIMIDINES, THIENOPYRIDINES, AND PYRROLOPYRIMIDINES AS B-RAF INHIBITORS | WYETH (US) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118276-A1 | THIENOPYRIMIDINES, THIENOPYRIDINES, AND PYRROLOPYRIMIDINES AS B-RAF INHIBITORS | BRAF, ARAF, RAF1 | BRAF 1/4885TRPV4 2674/4885RAF1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.